Literature DB >> 11522434

Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals.

H Rommelspacher1, M Smolka, L G Schmidt, J Samochowiec, M R Hoehe.   

Abstract

On the basis of various study results, it is suggested that the ethanol-induced activation of the endogenous opioid system may play an important role in mediating the reinforcing effects of ethanol. The mesolimbic dopamine reward system is activated by both ethanol and opioids, and genetic differences in the sensitivity of the endogenous opioid system to alcohol may be an important factor determining the risk for the development of excessive alcohol consumption. Thus, variants of the mu-opioid receptor (muOR) gene may confer vulnerability to alcohol dependence. Five exon 1 variants of the muOR were investigated in 327 alcohol-dependent and 340 healthy control subjects. The Val6 variant of the +17C/T polymorphism and the Asp40 variant of the +118A/G polymorphism showed a trend to an increased allele frequency in alcohol-dependent subjects. The latter polymorphism was investigated in more detail. The dopamine receptor agonist apomorphine causes an increase in growth hormone (GH) levels in the blood by stimulating the release of growth hormone-releasing hormone. beta-endorphin also activates this regulatory circuit. We found a blunted response in intoxicated alcohol-dependent subjects, but no difference in GH response between the groups of alcohol-dependent subjects with and without the variant Asp allele. However, alcohol-dependent subjects with the Asp allele showed a significantly higher GH response at day 7 after alcohol withdrawal and a tendency to lower novelty seeking. These results suggest to us that there is reduced dopaminergic neuronal activity in alcohol-dependent subjects with the muOR Asp40 allele, along with a compensating increase in dopamine receptor activity. The difference between the two groups of alcohol-dependent subjects can be demonstrated only under certain conditions such as alcohol withdrawal, which necessitates the adaptation of the neurones to a new homeostasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522434     DOI: 10.1016/s0741-8329(01)00139-2

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  19 in total

1.  A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women.

Authors:  Howard A Crystal; Sara Hamon; Matthew Randesi; Judith Cook; Kathryn Anastos; Jason Lazar; Chenglong Liu; Leigh Pearce; Elizabeth Golub; Victor Valcour; Kathleen M Weber; Susan Holman; Ann Ho; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2010-11-11       Impact factor: 4.280

2.  Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence.

Authors:  Huiping Zhang; Xingguang Luo; Henry R Kranzler; Jaakko Lappalainen; Bao-Zhu Yang; Evgeny Krupitsky; Edwin Zvartau; Joel Gelernter
Journal:  Hum Mol Genet       Date:  2006-02-13       Impact factor: 6.150

Review 3.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

4.  Convergent Balancing Selection on the Mu-Opioid Receptor in Primates.

Authors:  Carolyn G Sweeney; Juliette M Rando; Helen N Panas; Gregory M Miller; Donna M Platt; Eric J Vallender
Journal:  Mol Biol Evol       Date:  2017-07-01       Impact factor: 16.240

5.  The effect of alcohol priming on neural markers of alcohol cue-reactivity.

Authors:  Kelly E Courtney; Dara G Ghahremani; Lara A Ray
Journal:  Am J Drug Alcohol Abuse       Date:  2015-06-30       Impact factor: 3.829

6.  A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 7.  The pharmacogenetics of alcohol use disorder.

Authors:  Jermaine D Jones; Sandra D Comer; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-02-19       Impact factor: 3.455

8.  OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

Authors:  Gabor Oroszi; Raymond F Anton; Stephanie O'Malley; Robert Swift; Helen Pettinati; David Couper; Qiaoping Yuan; David Goldman
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

Review 9.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

10.  Initial evidence of an association between OPRM1 and adolescent alcohol misuse.

Authors:  Robert Miranda; Lara Ray; Alicia Justus; Lori A Meyerson; Valerie S Knopik; John McGeary; Peter M Monti
Journal:  Alcohol Clin Exp Res       Date:  2009-10-23       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.